← Human Trials & Peer-Reviewed Studies
Symptomatic and physiological responses to hypoglycaemia induced by human soluble insulin and the analogue Lispro human insulin
Plain-language guide to PMID 9400916 (1997): double-blind randomized controlled trial study of Insulin Lispro.
Key Facts
- PMID
- 9400916
- Journal
- Diabetic medicine : a journal of the British Diabetic Association
- Year
- 1997
- Study type
- Randomized Controlled Trial
- Authors
- McCrimmon RJ et al. (2 authors)
- DOI
- 10.1002/(SICI)1096-9136(199711)14:11<929::AID-DIA477>3.0.CO;2-4
What This Study Did, in Plain Language
What Was Tested
This randomized controlled trial paper looks at Insulin Lispro.
The aim of this study was to compare the glycaemic threshold for onset of the clinically detectable sympatho-adrenal (autonomic) reaction (defined as 'R') to hypoglycaemia induced by Lispro human insulin, with that induced by human soluble insulin (HS).
Why It Was Studied
The hypoglycaemia symptom profile, counterregulatory hormonal responses, and cognitive performance at R were also compared.
Sixteen patients with IDDM, aged 32.5 (20-45) (median (range)) years and duration of IDDM 3.0 (0.5-4.5) years participated in a randomized, double-blind study during which intravenous infusions of either Lispro or HS insulin (2.0 mU kg(-1) min(-1)) were used on separate occasions to lower the blood glucose to the level at which R was induced.
Who Took Part
The age groups tagged for this paper are adults, men only.
How the Study Was Run
The researchers set it up as a randomized and double-blind study.
Random assignment meant chance, not the researchers, decided who got Insulin Lispro and who got the comparison, which limits bias.
As a double-blind Insulin Lispro study, the assignments were hidden from both participants and investigators until the end.
What Was Measured
Sixteen patients with IDDM, aged 32.5 (20-45) (median (range)) years and duration of IDDM 3.0 (0.5-4.5) years participated in a randomized, double-blind study during which intravenous infusions of either Lispro or HS insulin (2.0 mU kg(-1) min(-1)) were used on separate occasions to lower the blood glucose to the level at which R was induced.
PubMed files the paper under topics including Blood Glucose, Blood Pressure, Cognition, Diabetes Mellitus, Type 1, Heart Rate, Hormones and Hypoglycemia.
What This Means in Plain Language
The paper is a randomized and double-blind study of Insulin Lispro.
The publication is from 1997 (Diabetic medicine : a journal of the British Diabetic Association), a journal based in England.
More context: the Insulin Lispro compound page, all human trials.
Our Notes on the Compound
Insulin Lispro: A rapid-acting mealtime insulin analog; brands include Humalog, Admelog and Lyumjev.
Related Pages
Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.